Clinical trial

Study of Surufatinib Combined With Sintilimab and SCRT in Advanced Solid Tumors

NCT05527821

StatusUNKNOWN

Study typeINTERVENTIONAL

Start date2022-09-30

PhasePHASE2

Study timeline

Study start (estimated)2022-09-30Date precision: day

Registry last updated2022-09-06

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Unresectable Advanced Solid Tumorsunresolved

Biliary Tract Tumors, Gastric Cancer, Small Cell Lung Cancerunresolved

Interventions

SurufatinibDRUG

Short course radiotherapyRADIATION

Sponsors & collaborators

Union Hospital, Tongji Medical College, Huazhong University of Science and Technologylead sponsor

Mapped research locations

WuhanHubei, China1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT05527821 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.